Luqa Pharmaceuticals Completes US$15M Funding

luqaLuqa Pharmaceuticals, a China-based specialty care company that markets innovative solutions in dermatology and other specialty areas, completed a US$15m round of funding.

The round was led by Morningside Ventures.

The company intends to use the funds to expand, develop and fund ongoing operations and commercialization of its product range.

Led by CEO Robert Braithwaite, Luqa Pharmaceuticals acquires, develops and commercializes innovative healthcare products. Its medical, corrective and aesthetic product lines are used mainly by physicians to enhance patients’ appearance. Incepted in 2010, the company launched its first product in 2013 and has now released an additional eight products, with three more expected in 2015.

FinSMEs

09/06/2015

 

Join the discussion